Quick Answer
Definium Therapeutics, Inc. reported Shares Outstanding of 98.78 million shares for fiscal year 2025.
Definium Therapeutics, Inc. Shares Outstanding — Annual History
| Fiscal Year | Shares Outstanding | YoY Change |
|---|---|---|
| 2025 | 98.78M | +31.5% |
| 2024 | 75.10M | +82.7% |
| 2023 | 41.10M | +8.2% |
| 2022 | 37.98M | +35.0% |
| 2021 | 28.13M | — |
Quarterly Shares Outstanding
| Quarter Ending | Shares Outstanding | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | 76.77M | -5.9% | +1.3% |
| June 30, 2025 | 75.80M | +5.2% | +0.4% |
| March 31, 2025 | 75.51M | +6.1% | +0.5% |
| December 31, 2024 | 75.10M | +82.7% | -8.0% |
| September 30, 2024 | 81.59M | +103.5% | +13.2% |
| June 30, 2024 | 72.08M | +85.7% | +1.3% |
| March 31, 2024 | 71.16M | +85.9% | +73.1% |
| December 31, 2023 | 41.10M | +8.2% | +2.5% |
- Definium Therapeutics, Inc. showed an increase of +31.5% in Shares Outstanding compared to the prior fiscal year.
- Over the 2021–2025 period, Definium Therapeutics, Inc.’s shares outstanding has grown by 251.2% (from 28.13 million shares to 98.78 million shares).
- The most recent figure is from Definium Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: